Ravulizumab in Pregnancies complicated by Severe Hypertensive Disorders

Overview

About this study

The purpose of this study is to analyze the use of ravulizumab, an inhibitor of complement activation, to target alternative complement pathway in patients with severe preeclampsia/ HELLP syndrome. The goal is to explore the role of ravulizumab as a novel therapy for severe preeclampsia/HELLP syndrome.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Pregnant female adults between 18 and 50 years old.
  • Individuals with < 34 0/7 weeks of gestation.
  • Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria:

  • Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
  • Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Eligibility last updated 11/16/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Maria Gonzalez Suarez, M.D., Ph.D.

Contact us for the latest status

Contact information:

Maria Gonzalez Suarez M.D., Ph.D.

(507) 284-4083

GonzalezSuarez.Maria@mayo.edu

More information

Publications

Publications are currently not available